• 1
    McDonald S, Excell L, Dent H. ANZDATA Registry Report. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2008.
  • 2
    Hjelmesaeth J, Hartmann A, Leivestad T et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006; 69: 58895.
  • 3
    Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 4
    Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 196372.
  • 5
    Colagiuri S, Dickenson S, Girgis S, Colagiuiri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Canberra: Diabetes Australia and the NHMRC, 2009.
  • 6
    Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 75572.
  • 7
    Ling HE, Sabet A, Djedjos S et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137: 63546.
  • 8
    Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995; 333: 55054.
  • 9
    Bosi E. Metformin – the gold standard in type 2 diabetes: What does the evidence tell us? Diabetes Obes. Metab. 2009; 11 (Suppl 2): 38.
  • 10
    Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. Kidney function and age are both predictors of pharmacokinetics of metformin. J. Clin. Pharmacol. 1995; 35: 1094102.
  • 11
    Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch. Intern. Med. 2006; 166: 19759.
  • 12
    Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia? Aust. Fam. Physician 2003; 32: 3834.
  • 13
    Rosand J, Friedberg J, Yang J. Fatal phenformin-associated lactic acidosis. Ann. Intern. Med. 1997; 127: 170.
  • 14
    Salpeter SR, Greyber E, Pasterrnak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2009; (1): CD002967.
  • 15
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch. Intern. Med. 2003; 163: 2594602.
  • 16
    Kamber N, Davis WA, Bruce DG, Davis TM. Metformin and lactic acidosis in an Australian community setting: The Fremantle Diabetes Study. Med. J. Aust. 2008; 188: 4469.
  • 17
    Tahrani AA, Varghese GI, Scarpello JH, Hanna FWF. Metformin, heart failure and lactic acidosis: is Metformin absolutely contraindicated? BMJ 2007; 355: 50812.
  • 18
    Pongwecharak J, Tengmeesri N, Malanusorn N, Panthong M, Pawangkapin N. Prescribing metformin in type 2 diabetes with a contraindication: Prevalence and outcome. Pharm. World Sci. 2009; 31: 4816.
  • 19
    Fux Otta CF, Wior M, Iraci GS et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial. Gynecol. Endocrinol. 2009; 8: 16.
  • 20
    Burgert TS, Duran EJ, Goldberg-Gell R et al. Short tem metabolic and cardiovascular effects of Metformin in markedly obese adolescents with normal glucose tolerance. Pediatr. Diabetes 2008; 9: 56776.
  • 21
    Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2008; 1: 15.
  • 22
    The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995; 47: 170320.
  • 23
    Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005; 353: 264353.
  • 24
    Turner RC, Holman RR, Cull CA, Stratton IM. Intensive blood glucose control with sulphanylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 8378.
  • 25
    Patel A. Intensive blood glucose control and vascular outcomes in patient with type 2 diabetes. N. Engl. J. Med. 2008; 358: 256072.
  • 26
    Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008; 358: 254559.
  • 27
    Ray KK, Seshasai SRK, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009; 373: 176572.
  • 28
    Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006; 355: 2427.
  • 29
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS34). Lancet 1998; 352: 85465.
  • 30
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 157789.
  • 31
    Kooy A, Jager J, Lehert P et al. Long term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 2009; 169: 61625.
  • 32
    Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 22448.
  • 33
    Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GMC. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 2005; 258: 25056.
  • 34
    Caballero AE, Delgado A, Aguilar–Salinas CA et al. The differential effects of metformin on makers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo – controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004; 8: 39435.
  • 35
    Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of Metformin in type 2 diabetes. Diabetes Obes. Metab. 2007; 9: 33036.
  • 36
    Bailey CJ. Treating insulin resistance in type 2 diabetes with Metformin and thiazolidinediones. Diabetes Obes. Metab. 2005; 7: 67591.
  • 37
    Ohira M, Miyashita Y, Ebisuno M et al. Effect of Metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract. 2007; 1: 3441.
  • 38
    Wulffele MG, Kooy A, De Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 2004; 256: 114.
  • 39
    Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial. Ann. Intern. Med. 2005; 142: 61119.
  • 40
    Libby G, Donnelly L, Donnan P, Alessi D, Morris A, Evans J. New Users of Metformin are at low risk of incident cancer. Diabetes Care 2009; 32: 162025.
  • 41
    Alessi D, Sakamoto K, Bayascas JR. LKB1 dependent signalling pathways. Annu. Rev. Biochem. 2006; 75: 13763.
  • 42
    Eurich D, McAlister F, Blackburn D, Johnson J. Benefits and harms of antidiabetic agents in patients with heart failure: Systematic review. BMJ 2007; 335: 497507.
  • 43
    Knowler WC, Barret-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393403.
  • 44
    Ratner RE, Christophi CA, Metzger BE et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. Endocr. Soc. 2008; 93: 47749.
  • 45
    National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 2005; 4 (Suppl 3): S1.
  • 46
    Kasiske BL, Snyder JJ, David G, Matas A. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 2003; 3: 17885.
  • 47
    Lachin JM, Christophi CA, Edelstein SL et al. Factors Associated with Diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007; 56: 11539.
  • 48
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwai F, Dulai G. Post-transplantation diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am. J. Transplant. 2005; 5: 243340.
  • 49
    Crutchlow MF, Bloom RD. Transplant-associated hyperglycemia: A new look at an old problem. Clin. J. Am. Soc. Nephrol. 2007; 2: 34355.
  • 50
    Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 111.
  • 51
    Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007; 7: 150614.
  • 52
    Romagnoli J, Citterio F, Nanni G et al. Incidence of post-transplant diabetes mellitus in kidney transplant recipients immunosuppressed with Sirolimus in combination with cyclosporine. Transplant. Proc. 2006; 38: 10346.
  • 53
    Cosio FG, Kudva Y, Van Der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005; 67: 241521.
  • 54
    Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: A pilot study. Transplantation 2001; 72: 13214.
  • 55
    Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 3538.
  • 56
    Kaplan B, Friedman G, Jacobs M et al. Potential Interaction of troglitazone and cyclosporine. Transplantation 1998; 65: 1399400.
  • 57
    Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr. Pract. 2008; 14: 97984.